The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia

被引：13

作者：

Al-Shaer M.H. ^{[1
]}

Choueiri N.E. ^{[1
]}

Suleiman E.S. ^{[1
]}

机构：

[1] Department of Internal Medicine, Hum. Cardiovasc. Physiol. Laboratory, Univ. of Iowa College of Medicine, Iowa City

来源：

Lipids in Health and Disease | / 3卷 / 1期

关键词：

Ezetimibe; Zetia; Cholesterol Absorption Inhibitors; Dyslipidemia; Hyperlipidemia; Hypercholesterolemia; Atherosclerosis; Sitosterolemia; Pleiotropic Effects of Statins; homozygous familial hypercholesterolemia;

D O I：

10.1186/1476-511X-3-22

中图分类号：

学科分类号：

摘要：

Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk of coronary heart disease. Ezetimibe is the first member of a new class of selective cholesterol absorption inhibitors. It impairs the intestinal reabsorption of both dietary and hepatically excreted biliary cholesterol. Ezetimibe is an effective and safe agent for lowering LDL-C and non HDL-C. Short term clinical trials have established the role of ezetimibe monotherapy and its use in combination with statins. Furthermore, ezetimibe and statin combination therapy increased the percentage of patients who achieved their LDL-C treatment goal. Studies using surrogate markers of atherosclerosis have suggested a possible role of ezetimibe in combating atherosclerosis. Ezetimibe provides an effective therapeutic strategy for the management of homozygous familial hypercholesterolemia (HoFH) and sitosterolemia. The lack of outcomes and long term safety data is attributed to the relatively recent introduction of this medication. © 2004 Al-Shaer et al; licensee BioMed Central Ltd.

引用

共 46 条

[1]

Ford E.S., Giles W.H., Dietz W.H., Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey, JAMA, 287, pp. 356-359, (2002)

[2]

Heart Disease and Stroke Statistics - 2004 Update, (2003)

[3]

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 25, pp. 3143-3421, (2002)

[4]

Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto Jr. A.M., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 20, pp. 1615-1622, (1998)

[5]

Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, pp. 1301-1307, (1995)

[6]

Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, pp. 1001-1009, (1996)

[7]

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)

[8]

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, pp. 1349-1357, (1998)

[9]

Ballantyne C.M., Low-density lipoproteins and risk for coronary artery disease, Am J Cardiol, 82, 9 A, (1998)

[10]

Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Arterioscler Thromb Vasc Biol, 24, (2004)

← 1 2 3 4 5 →